Compare CTNM & FLGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CTNM | FLGT |
|---|---|---|
| Founded | 2009 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 550.7M | 511.0M |
| IPO Year | 2024 | 2016 |
| Metric | CTNM | FLGT |
|---|---|---|
| Price | $9.57 | $24.18 |
| Analyst Decision | Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $21.43 | N/A |
| AVG Volume (30 Days) | ★ 596.9K | 324.7K |
| Earning Date | 11-03-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 0.46 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $18,730,000.00 |
| Revenue This Year | N/A | $3.85 |
| Revenue Next Year | N/A | $9.64 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.73 | $13.46 |
| 52 Week High | $17.79 | $31.04 |
| Indicator | CTNM | FLGT |
|---|---|---|
| Relative Strength Index (RSI) | 46.25 | 59.62 |
| Support Level | $8.59 | $18.82 |
| Resistance Level | $13.72 | $24.91 |
| Average True Range (ATR) | 0.77 | 1.42 |
| MACD | 0.23 | 0.43 |
| Stochastic Oscillator | 42.33 | 64.10 |
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in the laboratory services business and the therapeutic development business. The laboratory services business, which generates key revenue, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue, and Foreign.